Research must provide ‘more good news on outcomes’ while patients need simple an...

Hematology is one of few medical disciplines that have made significant steps in realizing the promise of personalized medicine. Together with ESMO and Eurocan Platform and in the context of our membership of the European Alliance for Personalised Medicine (EAPM), EHA was involved in the organization of a Roundtable  ‘Oncology/Haematology: How to provide the right prevention and treatment to the right patient at the right time’.

Read more

Sanquin Blood Supply will culture erythrocytes for transfusion purposes

Transfusion of erythrocytes is the most common form of cellular therapy. It rapidly restores the oxygen supply to the tissues in patients suffering from sudden blood loss, reduced erythrocyte production following for instance cytotoxic cancer treatment, or in patients suffering from chronic anemia due to congenital diseases such as sickle cell disease and thalassemia. Matching transfusions for ABO and Rh-D blood group antigens is in general sufficient for successful transfusion. However, over 300 additional blood group antigens are known, against which we do not normally generate antibodies, and that are not matched for in general transfusion practice.

Read more

Position of EHA on Access to Medicines

Access to medicines is a fundamental element of the human right to health. While recognizing the need to keep our health systems affordable, we see great danger in hematologists having to prioritize patients, substitute standard for improvised regimens or choose unproven treatment options. As part of our mission to promote excellence in clinical practice in hematology we call upon the EU to promote knowledge building, increase transparency and take evidence-based measures that remove unnecessary barriers to patient access to medicines in Europe.

Read more

Position of EHA on the Harmonization of Training and Education in Europe

Trainees and specialists in hematology must be fit for practice. It is our mission to promote excellence in education in European hematology. To improve patient care and public health it is essential to raise and maintain the skills and competences of hematologists to an equally high standard across European countries. Therefore, we aim to harmonize and improve training and education in hematology in Europe.

Read more

Position of EHA on Research Funding

It’s in the blood of hematologists to do research. It is our mission to promote research in European hematology. To sustain and improve research in blood disorders, it is essential to secure funding. Therefore, we seek to improve funding opportunities for research in blood disorders in Europe.

Read more

Position of EHA on Clinical Trials

It’s in the blood of hematologists to do research. It is our mission to promote research in European hematology. To sustain and improve the discovery (or the verification of the effects) of medicines to treat blood disorders it is essential that the requirements for clinical research add value, especially where investigator-driven research is concerned. Therefore we seek to improve the regulations for the performance of clinical trials of blood disorders in Europe.

Read more

Position of EHA on Personalized Medicine

Personalized medicine is revolutionizing the way blood disorders are managed and researched. It is our mission to promote excellence in research, education, and clinical practice in hematology. To achieve this, it is important to promote personalized medicine. Therefore, we seek to improve the conditions that allow for the support of personalized medicine.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

Stockholm, June 14, 2013 Dr Wyndham Wilson will give an update on recent developments in the treatment of lymphomas with small molecules. The last 30 years have seen a plethora of treatments for diffuse large B-cell lymphoma (DLBCL) but few advances have been made. Recent studies have identified B-cell receptor signaling as critical for many B-cell lymphomas including the most common type, called diffuse large B-cell lymphoma (DLBCL). Recent studies have shown that DLBCL is actually not a single disease but at least 3 different diseases, each with its own critical abnormalities that allow it to survive as a malignancy.  The most difficult to treat type of DLBCL is called the Activated B-cell (ABC) subtype, which is dependent on abnormal signaling of the B-cell receptor (BCR). Work by Dr. Lou Staudt has shown that these tumors will die when this pathway is inhibited.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

Stockholm, June 14, 2013 Dr Jesus San-Miguel will present promising results of a phase 3 study in multiple myeloma.
Treatment for patients with multiple myeloma (MM) has improved over the last decade due to the introduction of new drugs such as lenalidomide and bortezomib. However, after receiving multiple treatments, MM patients often become resistant (refractory) to these drugs and have an average survival of only 9 months.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an...

Stockholm, June 14, 2013 Dr Henk Lokhorst will present the results from a phase I/II study in advanced Multiple Myeloma.
Multiple myeloma is the second most common hematological cancer. It is a cancer of plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.

Read more

Mini-hormone fights iron

Stockholm, June 14, 2013 Dr Elizabeta Nemeth will present findings of a study in patients with iron overload disorders that will contribute to the design of a potential new treatment at the 18th Congress of the European Hematology Association in Stockholm.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROL...

Stockholm, June 14, 2013 Dr Ross Levine will present the results from a study on targeting the JAK-STAT pathway in myeloproliferative neoplasms.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes ...

Stockholm, June 14, 2013 Dr Valentin Goede will present promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology Association in Stockholm.

Read more

Press release: 18th Congress of the European Hematology Association in Stockholm...

Since 2010 the European Hematology Association (EHA) and the Wallace H Coulter Foundation (WHCF) have been in a close partnership, in which EHA was the beneficiary of generous donations for its projects. The support of the WHCF has been the prime mover for the setup of the EHA-ASH Translational Research Training in Hematology (TRTH) program and an important contributor towards the vast expansion of EHA’s outreach program. Both programs have had a major impact on the Association’s array of activities and global network.

The importance of the achievements of Wallace Coulter, the inventor of the Coulter Counter - the most valuable tool in the hematology laboratory, as a person and his organization cannot be underestimated for the hematological community as well as for EHA due to the Foundation’s support. EHA is glad to be able to pay tribute and commemorate the 100th birthday of Wallace Coulter.

Read more

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be ...

This year the Scientific Working Group Session on hematopoietic stem cells will focus on the recent advance in the field of “Induced Pluripotent Stem Cells (IPSC)”.

Read more